288 related articles for article (PubMed ID: 22233347)
21. Simvastatin reduces secondary brain injury caused by cortical contusion in rats: possible involvement of TLR4/NF-kappaB pathway.
Chen G; Zhang S; Shi J; Ai J; Qi M; Hang C
Exp Neurol; 2009 Apr; 216(2):398-406. PubMed ID: 19166837
[TBL] [Abstract][Full Text] [Related]
22. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects.
Sironi L; Gianazza E; Gelosa P; Guerrini U; Nobili E; Gianella A; Cremonesi B; Paoletti R; Tremoli E
Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):598-603. PubMed ID: 15681303
[TBL] [Abstract][Full Text] [Related]
23. Intravenous rosuvastatin for acute stroke treatment: an animal study.
Prinz V; Laufs U; Gertz K; Kronenberg G; Balkaya M; Leithner C; Lindauer U; Endres M
Stroke; 2008 Feb; 39(2):433-8. PubMed ID: 18162625
[TBL] [Abstract][Full Text] [Related]
24. Use of statins for the treatment of spontaneous intracerebral hemorrhage: results of a pilot study.
Tapia-Perez H; Sanchez-Aguilar M; Torres-Corzo JG; Rodriguez-Leyva I; Gonzalez-Aguirre D; Gordillo-Moscoso A; Chalita-Williams C
Cent Eur Neurosurg; 2009 Feb; 70(1):15-20. PubMed ID: 19197830
[TBL] [Abstract][Full Text] [Related]
25. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
[TBL] [Abstract][Full Text] [Related]
26. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury.
Laskowitz DT; McKenna SE; Song P; Wang H; Durham L; Yeung N; Christensen D; Vitek MP
J Neurotrauma; 2007 Jul; 24(7):1093-107. PubMed ID: 17610350
[TBL] [Abstract][Full Text] [Related]
27. Statins and the response to myocardial injury.
Scalia R
Am J Cardiovasc Drugs; 2005; 5(3):163-70. PubMed ID: 15901204
[TBL] [Abstract][Full Text] [Related]
28. The effect of rosuvastatin in a murine model of influenza A infection.
Radigan KA; Urich D; Misharin AV; Chiarella SE; Soberanes S; Gonzalez A; Perlman H; Wunderink RG; Budinger GR; Mutlu GM
PLoS One; 2012; 7(4):e35788. PubMed ID: 22536437
[TBL] [Abstract][Full Text] [Related]
29. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
[TBL] [Abstract][Full Text] [Related]
30. Pleiotropic effects of long-term monotherapy with rosuvastatin in dogs with moderate heart failure.
Chello M; Spadaccio C
Cardiology; 2013; 124(1):36-7. PubMed ID: 23295545
[No Abstract] [Full Text] [Related]
31. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity.
Zacco A; Togo J; Spence K; Ellis A; Lloyd D; Furlong S; Piser T
J Neurosci; 2003 Dec; 23(35):11104-11. PubMed ID: 14657168
[TBL] [Abstract][Full Text] [Related]
32. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.
Kapur NK
Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):161-75. PubMed ID: 17338662
[TBL] [Abstract][Full Text] [Related]
33. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the efficacy of different statins in murine collagen-induced arthritis.
Palmer G; Chobaz V; Talabot-Ayer D; Taylor S; So A; Gabay C; Busso N
Arthritis Rheum; 2004 Dec; 50(12):4051-9. PubMed ID: 15593180
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
36. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury.
Chen XR; Besson VC; Beziaud T; Plotkine M; Marchand-Leroux C
J Pharmacol Exp Ther; 2008 Sep; 326(3):966-74. PubMed ID: 18562561
[TBL] [Abstract][Full Text] [Related]
38. Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type A receptor.
Zhu T; Zhang W; Wang DX; Huang NW; Bo H; Deng W; Deng J
Chin Med J (Engl); 2012 Apr; 125(8):1457-64. PubMed ID: 22613653
[TBL] [Abstract][Full Text] [Related]
39. Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats.
Mooradian AD; Haas MJ
Am J Ther; 2007; 14(1):41-5. PubMed ID: 17303974
[TBL] [Abstract][Full Text] [Related]
40. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
